Table 2. Demographic characteristic of responders and non-responders and intra-groups of non-responders finished the study.
| Stage 1 |
Stage 2 |
|||||
|---|---|---|---|---|---|---|
| Responders | Non-responders | MF + Placebo | MF + OXY | Placebo + OXY | Placebo + Placebo | |
| Number | 44 | 68 | 15 | 16 | 16 | 16 |
| Sex (Male:Female) | 21:23 | 33:35:00 | 8:07 | 7:09 | 8:08 | 9:07 |
| Age (months) | 91.4 ± 22.0 | 93.1 ± 26.8 | 93.8 ± 22.5 | 98.3 ± 23.9 | 97.2 ± 21.0 | 95.2 ± 24.5 |
| Total score | 16.1 ± 1.4 | 15.9 ± 1.3 | 15.9 ± 1.8 | 16.5 ± 1.5 | 16.3 ± 1.6 | 15.3 ± 1.5 |
| Nasal congestion score | 2.7 ± 0.3 | 2.8 ± 0.2 | 2.6 ± 0.3 | 2.7 ± 0.3 | 2.5 ± 0.3 | 2.6 ± 0.4 |
| Itchy nose score | 2.5 ± 0.2 | 2.4 ± 0.3 | 2.6 ± 0.2 | 2.5 ± 0.4 | 2.5 ± 0.3 | 2.4 ± 0.3 |
| Sneezing score | 2.7 ± 0.3 | 2.5 ± 0.4 | 2.6 ± 0.3 | 2.5 ± 0.3 | 2.6 ± 0.3 | 2.4 ± 0.3 |
| Rhinorrhea score | 2.4 ± 0.3 | 2.5 ± 0.3 | 2.5 ± 0.3 | 2.6 ± 0.3 | 2.4 ± 0.3 | 2.5 ± 0.2 |
| Snoring score | 2.6 ± 0.4 | 2.7 ± 0.2 | 2.7 ± 0.2 | 2.6 ± 0.2 | 2.7 ± 0.3 | 2.6 ± 0.2 |
| Cough score | 2.4 ± 0.3 | 2.3 ± 0.2 | 2.2 ± 0.3 | 2.3 ± 0.4 | 2.2 ± 0.3 | 2.4 ± 0.2 |
| Adenoid/choana ratio (%) | 85.4 ± 11.0 | 87.2 ± 11.3 | 86.1 ± 12.0 | 83.4 ± 11.1 | 86.4 ± 11.5 | 85.1 ± 11.2 |
| Nasal volume (cm3) | 12.2 ± 0.8 | 11.0 ± 0.6* | 10.5 ± 0.6 | 11.2 ± 0.4 | 11.3 ± 0.5 | 11.1 ± 0.4 |
| BMI (kg/m2) | 19.2 ± 2.3 | 20.8 ± 3.0 | 18.3 ± 3.3 | 22.4 ± 2.0 | 21.6 ± 2.3 | 20.9 ± 3.1 |
| ECP (ng/ml) | 39.2 (4.0–104.0) | 29.9 (3.6–119.0) | 32.2 (3.6–119.0) | 41.9 (3.6–119.0) | 36.8 (3.6–119.0) | 31.2 (3.6–119.0) |
| TIgE (IU/ml) | 393.2 (120.5–902.0) | 459.0 (167.3–870.0) | 383.2 (188.3–1010.0) | 406.0 (213.3–854.0) | 515.2 (237.3–970.0) | 386.0 (245.3–970.0) |
| Duration of disease (year) | 1.7 ± 0.4 | 1.5 ± 0.7 | 1.6 ± 0.5 | 1.7 ± 0.6 | 1.6 ± 0.5 | 1.5 ± 0.5 |
*Compared with Reponders group, P < 0.05.